Gliomas, the most common form of brain tumors of the adult CNS, originate from neuroepithelial tissue and are classified morphologically as astrocytic, oligodendroglial, ependymal, and choroid plexus tumors. Glioblastoma multiforme (grade IV astrocytoma; GBM) is one of the most aggressive forms of brain tumors and a primary area of focus for the Neurooncology Group at MSCTR.
Gliomas, originate from the neuro-epithelial tissue and are classified morphologically as astrocytic, oligodendroglial, ependymal and choroid plexus tumors. Glioblastoma multiforme (grade IV astrocytoma; GBM) is one of the most aggressive, invasive, and destructive malignancies and has attracted clinical attention globally. In addition to uncontrolled proliferation and diffuse tissue invasion, neuro-degeneration is another attribute and a hall mark of malignant gliomas, the mechanism of which is poorly understood. Thus, there may be several processes that may be common between gliomas and neuro-degenerative disorders.
The focus of the Neuro-oncology Group at MSCTR will be:
To continue the discovery effort of understanding these tumors and the dynamics of associated molecular patterns from a clinical perspective. Also to relate the findings to neuro-degenerative conditions.
To develop well defined strategies, using the data that is already available, for translation to diagnostic, prognostic or therapeutic applications.
We envision implementation of the two arms in parallel, through a multi-disciplinary team effort, involving basic scientists with expertise in high throughput technologies, cell biologists, clinicians and informaticians. Embedded in these efforts will be the mission of mentoring young clinicians and research scientists who will lead MSCTR both as independent scientists and as a well-coordinated team directed towards improved neuro oncology practices. This will ensure continued institutional efforts. Gliomas, particularly Glioblastoma, are one of the most targeted tumors in clinical oncology research globally. Hence, the center will aim for networking with other national and international clinical centers in our efforts to formulate pioneering treatment models for malignant Glioblastoma.